Disease Landscape and Forecast Insights

Despite the large number of currently marketed antiepileptic drugs (AEDs), important unmet needs remain for new therapies to treat refractory epilepsy and seizure syndromes such as Lennox-Gastaut…

Epilepsy is a heterogeneous condition requiring individualized treatment—especially for patients who are persistently refractory to treatment. Neurologists consider many factors when selecting…

Epilepsy, which afflicts approximately 4.7 million people in the G7 according to DRGepidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s…

DRG epidemiologists estimate that 40% of epilepsy patients experience generalized-onset seizures (GOS). The most commonly prescribed early-line treatments for GOS are older antiepileptic drugs (…

Childhood absence epilepsy (CAE) is characterized by frequent and brief absence seizures in children aged 4-12 and is diagnosed in approximately 10-15% of all childhood epilepsies. Only a handful…

Epilepsy, which afflicts approximately 4.7 million people in the G7 according to DRGepidemiology, is a heterogeneous condition requiring individualized treatment based largely on a patient’s…

Market Outlook Epilepsy is a heterogeneous condition requiring individualized treatment. Neurologists consider many factors when selecting among the numerous first-, second-, and third-…

DRG estimates that 60% of epilepsy patients experience partial-onset seizures (POS). More than two dozen antiepileptic drugs (AEDs) are available in the United States and Europe—the majority of…

DRG estimates that 60% of epilepsy patients experience partial-onset seizures (POS). More than two dozen antiepileptic drugs (AEDs) are available in the United States and Europe—the majority of…

Approximately million patients in the seven major pharmaceutical markets under study are diagnosed with epilepsy, a debilitating collection of seizure disorders that affect patients’ quality of…

Dravet syndrome (DS) is a rare, severe, pediatric-onset form of epilepsy characterized by developmental delay or regression and multiple seizure types. Only Diacomit (Biocodex’s stiripentol) is…

Epilepsy is a heterogeneous condition requiring individualized treatment. Neurologists consider many factors when selecting among the numerous first-, second-, and third-generation anti-epileptic (…